Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masofaniten + Enzalutamide in mCRPC
NCT05075577Phase 2Terminated
- Sponsor
- ESSA Pharma
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of masofaniten in metastatic castration-resistant prostate cancer (mCRPC), sponsored by ESSA Pharma. Started Dec 2021; status: terminated.
02
Drugs
masofaniten
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05075577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075577.